Drugs / MK-4334
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05136690 | Apr → Sep 2022 | schizophrenia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03740178 | Sep 2019 → Feb 2020 | Alzheimer disease, cognitive impairment with or without cerebellar ataxia | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4334 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05136690 ↗ |
| Route | Oral | “administered orally” NCT03740178 ↗ |